>>Avastin is a biologic approved for metastatic colorectal cancer and nonsmall cell lung cancer. Onyx will have data on its phase three trial of Nexavar for lung cancer in 2008. If Nexavar is approved for that disease, the two could compete, Liang says.
"It's possible Nexavar could supersede Avastin because an oral drug is more convenient to take," he said.
LOOKING AHEAD
Onyx will also have phase three data on Nexavar's effects on metastatic melanoma in 2008.
The company will look for noncancer uses as well, Renton says. One could be wet macular degeneration, which some doctors treat with Avastin.<<
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.